Jane Street Group, LLC Bluebird Bio, Inc. Transaction History

Jane Street Group, LLC

  • $445 Billion
  • Q3 2024

A detailed history of Jane Street Group, LLC transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 259,219 shares of BLUE stock, worth $108,871. This represents 0.0% of its overall portfolio holdings.

Number of Shares
259,219
Previous 1,097,978 76.39%
Holding current value
$108,871
Previous $1.08 Million 87.55%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$0.47 - $1.35 $394,216 - $1.13 Million
-838,759 Reduced 76.39%
259,219 $134,000
Q2 2024

Aug 14, 2024
BUY
$0.85 - $1.26 $249,226 - $369,442
293,208 Added 36.43%
1,097,978 $1.08 Million
Q1 2024

May 15, 2024
BUY
$0.91 - $1.75 $421,691 - $810,944
463,397 Added 135.75%
804,770 $1.03 Million
Q4 2023

Feb 14, 2024
SELL
$1.32 - $4.83 $350,735 - $1.28 Million
-265,709 Reduced 43.77%
341,373 $471,000
Q3 2023

Nov 14, 2023
SELL
$3.02 - $4.05 $1.05 Million - $1.4 Million
-346,213 Reduced 36.32%
607,082 $1.85 Million
Q2 2023

Aug 14, 2023
BUY
$2.79 - $5.03 $1.23 Million - $2.21 Million
439,219 Added 85.44%
953,295 $3.14 Million
Q1 2023

May 15, 2023
BUY
$3.14 - $8.22 $534,038 - $1.4 Million
170,076 Added 49.44%
514,076 $1.63 Million
Q4 2022

Feb 14, 2023
SELL
$5.77 - $8.49 $1.7 Million - $2.49 Million
-293,796 Reduced 46.06%
344,000 $2.38 Million
Q3 2022

Nov 14, 2022
BUY
$3.75 - $7.39 $1.29 Million - $2.54 Million
344,373 Added 117.36%
637,796 $4.04 Million
Q2 2022

Aug 16, 2022
BUY
$2.94 - $5.23 $718,547 - $1.28 Million
244,404 Added 498.59%
293,423 $1.22 Million
Q1 2022

May 17, 2022
SELL
$4.07 - $10.6 $536,446 - $1.4 Million
-131,805 Reduced 72.89%
49,019 $237,000
Q4 2021

Feb 15, 2022
BUY
$8.96 - $16.31 $424,650 - $772,996
47,394 Added 35.52%
180,824 $1.83 Million
Q3 2021

Nov 16, 2021
BUY
$11.24 - $21.0 $290,767 - $543,249
25,869 Added 24.05%
133,430 $2.55 Million
Q2 2021

Aug 16, 2021
SELL
$18.04 - $22.09 $1.11 Million - $1.36 Million
-61,711 Reduced 36.46%
107,561 $3.44 Million
Q1 2021

May 18, 2021
BUY
$16.59 - $33.89 $1.02 Million - $2.07 Million
61,197 Added 56.62%
169,272 $5.1 Million
Q4 2020

Feb 17, 2021
BUY
$27.5 - $37.92 $326,177 - $449,769
11,861 Added 12.33%
108,075 $4.68 Million
Q3 2020

Nov 17, 2020
BUY
$34.44 - $43.75 $1.16 Million - $1.48 Million
33,807 Added 54.17%
96,214 $5.19 Million
Q2 2020

Aug 17, 2020
BUY
$27.12 - $45.97 $1.43 Million - $2.43 Million
52,838 Added 552.18%
62,407 $3.81 Million
Q1 2020

May 15, 2020
SELL
$26.16 - $63.5 $740,144 - $1.8 Million
-28,293 Reduced 74.73%
9,569 $440,000
Q4 2019

Feb 14, 2020
BUY
$46.96 - $61.67 $560,984 - $736,709
11,946 Added 46.1%
37,862 $3.32 Million
Q3 2019

Nov 14, 2019
BUY
$59.47 - $93.1 $132,320 - $207,147
2,225 Added 9.39%
25,916 $2.38 Million
Q2 2019

Aug 15, 2019
BUY
$75.84 - $105.21 $216,371 - $300,164
2,853 Added 13.69%
23,691 $3.01 Million
Q1 2019

May 16, 2019
BUY
$64.44 - $104.11 $465,063 - $751,361
7,217 Added 52.98%
20,838 $3.28 Million
Q4 2018

Feb 15, 2019
SELL
$59.1 - $93.26 $91,664 - $144,646
-1,551 Reduced 10.22%
13,621 $1.35 Million
Q3 2018

Nov 14, 2018
SELL
$88.86 - $117.49 $1.76 Million - $2.33 Million
-19,811 Reduced 56.63%
15,172 $2.22 Million
Q2 2018

Aug 15, 2018
BUY
$99.64 - $127.59 $2.66 Million - $3.41 Million
26,745 Added 324.65%
34,983 $5.49 Million
Q1 2018

May 15, 2018
SELL
$105.8 - $150.94 $1.16 Million - $1.65 Million
-10,930 Reduced 57.02%
8,238 $1.41 Million
Q4 2017

Feb 15, 2018
BUY
$81.25 - $130.7 $249,031 - $400,595
3,065 Added 19.03%
19,168 $3.41 Million
Q3 2017

Nov 14, 2017
BUY
$57.74 - $91.42 $929,787 - $1.47 Million
16,103
16,103 $2.21 Million

Others Institutions Holding BLUE

# of Institutions
151
Shares Held
63.4M
Call Options Held
264K
Put Options Held
428K
View Full List

About bluebird bio, Inc.

BLUE Quotes by TradingView
  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $32.4M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email